Pre-Eclampsia - Pipeline Insight, 2021
This report can be delivered to the clients within 48-72 Hours
DelveInsight’s, “Pre-Eclampsia – Pipeline Insight, 2021,” report provides comprehensive insights about companies and pipeline drugs in the Pre-Eclampsia pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
Pre-Eclampsia : Overview
Preeclampsia is a pregnancy complication characterized by high blood pressure and signs of damage to another organ system, most often the liver and kidneys. Pre-eclampsia is a combination of hypertension (raised blood pressure) and proteinuria in pregnancy (the presence of protein in your urine). It generally develops during the third trimester. The condition affects around 5% to 8% of pregnancies and presents serious health consequences to mothers and babies. There is not a single cause, but some potential causes include: genetic factors and blood vessel problems. Left untreated, preeclampsia can lead to serious — even fatal — complications for both mother and baby.
“Abnormal Glucose Tolerance - Pipeline Insight, 2021” report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Abnormal Glucose Tolerance pipeline landscape is provided which includes the disease overview and Abnormal Glucose Tolerance treatment guidelines. The assessment part of the report embraces, in depth Abnormal Glucose Tolerance commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Abnormal Glucose Tolerance collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Pre-Eclampsia Emerging Drugs Chapters
This segment of the Pre-Eclampsia report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Pre-Eclampsia Emerging Drugs
KW3357: Kyowa Kirin Co., Ltd.
KW-3357 is an antithrombin (AT) drug created through the technology of recombinant DNA and sugar-chain control, which is a recombinant AT preparation with the same amino acid sequence and the same type of sugar chain structure as human natural AT. AT inhibits blood coagulation by forming a complex with the coagulation factor of proteolytic enzyme. In Japan, KW-3357 has been approved for the treatments of thrombophilia due to congenital AT deficiency (CAD) and disseminated intravascular coagulation (DIC) since July, 2015 and commercialized under the brand name of ACOALAN. KW3357 is currently in phase III stage of development by Kyowan Kirin Co.,Ltd in collaboration with Japan Blood Products Organization for Preeclampsia.
rhC1INH protein replacement therapy: Pharming Group
Pharming Group is developing a rhC1INH protein replacement therapy for the treatment of pre-eclampsia. Pre-eclampsia is a life-threatening multisystem disorder in pregnancies leading to maternal and neonatal mortality and morbidity, usually first appearing as hypertension and proteinuria. Pharming Group had initiated the therapy in 2019 and was in phase I/II of development, but was halted due to COVID-19.
Further product details are provided in the report……..
Pre-Eclampsia : Therapeutic Assessment
This segment of the report provides insights about the different Pre-Eclampsia drugs segregated based on following parameters that define the scope of the report, such as:
Major Players in Pre-Eclampsia
There are several companies which are developing the therapies for Pre-Eclampsia . The companies which have their Pre-Eclampsia drug candidates in the mid to advanced stage, i.e. phase III include, Kyowa Kirin Co.,Ltd. and others.
Phases
DelveInsight’s report covers products under different phases of clinical development like
Pre-Eclampsia pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
Pre-Eclampsia : Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Pre-Eclampsia therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Pre-Eclampsia drugs.
Report Highlights
The companies and academics are working to assess challenges and seek opportunities that could influence Pre-Eclampsia R&D. The therapies under development are focused on novel approaches to treat/improve Pre-Eclampsia .
Pre-Eclampsia Report Insights
Current Treatment Scenario and Emerging Therapies:
DelveInsight’s, “Pre-Eclampsia – Pipeline Insight, 2021,” report provides comprehensive insights about companies and pipeline drugs in the Pre-Eclampsia pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
Pre-Eclampsia : Overview
Preeclampsia is a pregnancy complication characterized by high blood pressure and signs of damage to another organ system, most often the liver and kidneys. Pre-eclampsia is a combination of hypertension (raised blood pressure) and proteinuria in pregnancy (the presence of protein in your urine). It generally develops during the third trimester. The condition affects around 5% to 8% of pregnancies and presents serious health consequences to mothers and babies. There is not a single cause, but some potential causes include: genetic factors and blood vessel problems. Left untreated, preeclampsia can lead to serious — even fatal — complications for both mother and baby.
“Abnormal Glucose Tolerance - Pipeline Insight, 2021” report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Abnormal Glucose Tolerance pipeline landscape is provided which includes the disease overview and Abnormal Glucose Tolerance treatment guidelines. The assessment part of the report embraces, in depth Abnormal Glucose Tolerance commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Abnormal Glucose Tolerance collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Pre-Eclampsia Emerging Drugs Chapters
This segment of the Pre-Eclampsia report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Pre-Eclampsia Emerging Drugs
KW3357: Kyowa Kirin Co., Ltd.
KW-3357 is an antithrombin (AT) drug created through the technology of recombinant DNA and sugar-chain control, which is a recombinant AT preparation with the same amino acid sequence and the same type of sugar chain structure as human natural AT. AT inhibits blood coagulation by forming a complex with the coagulation factor of proteolytic enzyme. In Japan, KW-3357 has been approved for the treatments of thrombophilia due to congenital AT deficiency (CAD) and disseminated intravascular coagulation (DIC) since July, 2015 and commercialized under the brand name of ACOALAN. KW3357 is currently in phase III stage of development by Kyowan Kirin Co.,Ltd in collaboration with Japan Blood Products Organization for Preeclampsia.
rhC1INH protein replacement therapy: Pharming Group
Pharming Group is developing a rhC1INH protein replacement therapy for the treatment of pre-eclampsia. Pre-eclampsia is a life-threatening multisystem disorder in pregnancies leading to maternal and neonatal mortality and morbidity, usually first appearing as hypertension and proteinuria. Pharming Group had initiated the therapy in 2019 and was in phase I/II of development, but was halted due to COVID-19.
Further product details are provided in the report……..
Pre-Eclampsia : Therapeutic Assessment
This segment of the report provides insights about the different Pre-Eclampsia drugs segregated based on following parameters that define the scope of the report, such as:
Major Players in Pre-Eclampsia
There are several companies which are developing the therapies for Pre-Eclampsia . The companies which have their Pre-Eclampsia drug candidates in the mid to advanced stage, i.e. phase III include, Kyowa Kirin Co.,Ltd. and others.
Phases
DelveInsight’s report covers products under different phases of clinical development like
- Late-stage products (Phase III )
- Early-stage products (Phase I/II and Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
Pre-Eclampsia pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
- Subcutaneous
- Intravenous
- Oral
- Molecule Type
- Replacement Therapy
- Physiological Saline
- Antihypertensive
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
Pre-Eclampsia : Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Pre-Eclampsia therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Pre-Eclampsia drugs.
Report Highlights
The companies and academics are working to assess challenges and seek opportunities that could influence Pre-Eclampsia R&D. The therapies under development are focused on novel approaches to treat/improve Pre-Eclampsia .
Pre-Eclampsia Report Insights
- Pre-Eclampsia Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Pre-Eclampsia drugs?
- How many Pre-Eclampsia drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Pre-Eclampsia ?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Pre-Eclampsia therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Pre-Eclampsia and their status?
- What are the key designations that have been granted to the emerging drugs?
- Kyowa Kirin Co., Ltd
- Pharming Group
- Amag Pharmaceuticals
- MirZyme
- KW3357
- rhC1INH protein replacement therapy
- AMAG-423
- MZe686
Introduction
Executive Summary
Pre-Eclampsia : Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Pre-Eclampsia – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
Pre-Eclampsia companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Pre-Eclampsia Collaboration Deals
Company-Company Collaborations (Licensing / Partnering) Analysis
Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase III)
Comparative Analysis
KW 3357: Kyowa Kirin Co., Ltd.
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I/II)
Comparative Analysis
rhC1INH protein replacement therapy: Pharming Group
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
Comparative Analysis
Drug Name: Company Name
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
Pre-Eclampsia Key Companies
Pre-Eclampsia Key Products
Pre-Eclampsia - Unmet Needs
Pre-Eclampsia - Market Drivers and Barriers
Pre-Eclampsia - Future Perspectives and Conclusion
Pre-Eclampsia Analyst Views
Pre-Eclampsia Key Companies
Appendix
Executive Summary
Pre-Eclampsia : Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Pre-Eclampsia – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
Pre-Eclampsia companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Pre-Eclampsia Collaboration Deals
Company-Company Collaborations (Licensing / Partnering) Analysis
Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase III)
Comparative Analysis
KW 3357: Kyowa Kirin Co., Ltd.
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I/II)
Comparative Analysis
rhC1INH protein replacement therapy: Pharming Group
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
Comparative Analysis
Drug Name: Company Name
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
Pre-Eclampsia Key Companies
Pre-Eclampsia Key Products
Pre-Eclampsia - Unmet Needs
Pre-Eclampsia - Market Drivers and Barriers
Pre-Eclampsia - Future Perspectives and Conclusion
Pre-Eclampsia Analyst Views
Pre-Eclampsia Key Companies
Appendix
LIST OF TABLES
Table 1 Total Products for Pre-Eclampsia
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
Table 1 Total Products for Pre-Eclampsia
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
LIST OF FIGURES
Figure 1 Total Products for Pre-Eclampsia
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
Figure 1 Total Products for Pre-Eclampsia
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
